Unveiling Innovation: Introducing the DxC 500i Clinical Analyzer

Watch as Chelsea Creech, Global Product Marketing Manager, and Alberto Scandroglio, HGM Marketing Leader in Clinical Chemistry/Immunoassay, unveil the DxC 500i Clinical Analyzer. Discover how the DxC 500i analyzer powers clinical chemistry and immunoassay testing in one space-saving package—so you can deliver the high-quality results your patients and care teams need, when they need them.

Interested in learning more about the DxC 500i Clinical Analyzer? Visit now
Speaker Speech
Speaker 1: Let's welcome to the stage Chelsea Creech, Global Product Marketing Manager, and Alberto Scandroglio, High Growth Markets Marketing Leader, Clinical Chemistry/Immunoassay.
Chelsea Creech: Hello everyone. Thank you for being here with us today and welcome to Beckman Coulter's Dubai Vision Center. Alberto and I are honored to be here to unveil our latest innovation and share how we can relentlessly reimagine health care one diagnosis at a time.
Alberto Scandroglio: Introducing the DxC 500i. Meet your partner for chemistry and immunoassay with simplified workflow for your low-volume laboratory.
Chelsea Creech: The key principle of how we conduct our business and shape our organization at Beckman Coulter is around the feedback we get from our customers. When customers talk, we listen, and most importantly, we apply.
Alberto Scandroglio: Chelsea, I'm assuming this principle of customer talk, we listen has been used by the Beckman Coulter team in developing this new analyzer as well, the DxC 500i.
Chelsea Creech: That's right, Alberto. We meticulously engineered the DxC 500i Analyzer for steadfast performance, practical simplicity, and trusted clinical quality, which directly addresses the key feedback we received from our customers, empowering you with actionable insights for clinicians to deliver the best possible care to patients even faster.
Alberto Scandroglio: That sounds quite exciting, Chelsea. Thank you very much. So you mentioned steadfast performance. How does the DxC 500i deliver that steadfast performance as a low-volume analyzer?
Chelsea Creech: This is a great question. Let me introduce FlexMode operation. FlexMode operations enables you to continuously and concurrently load chemistry and immunoassay, shared and stat samples, and empowers you to run maintenance and run samples at the same time. FlexMode maintenance gives you flexibility and control over your schedule. Run maintenance on clinical chemistry while running immunoassay testing and vice versa, ensuring uninterrupted workflow. What also sets FlexMode apart is its unique ability to intelligently prioritize testing, and manage repeat, re-run seamlessly without operator intervention, and seamlessly introduce a new rack as soon as another one is offloaded. This not only enhances efficiency, but ensures that your critical samples are given the priority that they deserve.
Alberto Scandroglio: Well, thank you very much for sharing all these great features as well. So we learned a lot about FlexMode operation. I would like also to learn more about the practical simplicity of the analyzer that you mentioned a minute ago. So how does this really benefits our customer?
Chelsea Creech: So embarking on the journey of practical simplicity, with the DxC 500i software user interface means not just streamlined task, but a transformative experience. This intuitive and user-friendly platform is designed to simplify your workflow, ensuring that every interaction is effortlessly guided. By offering proactive notifications for crucial aspects like calibration, quality control, and reagent replenishment, our software user interface becomes your proactive companion, eliminating guesswork. It's not just about ease, it's about practical and simplified approach that enhances precision, reduces errors, and ultimately elevates your entire laboratory experience.
Alberto Scandroglio: Sounds like this analyzer is really extremely easy to use. Something else that was important to our customer was as well trusted clinical quality. What does this mean for DxC 500i? How does this analyzer help our customer?
Chelsea Creech: With unwavering commitment to trusted clinical quality, the DxC 500i is poised to elevate your laboratory network to new height. Our Six Sigma chemistry assays ensured unmatched quality, establishing a new gold standard for laboratory performance. What truly distinguishes us is our dedication to common reagents across clinical chemistry and immunoassay, fostering a unified and standardized testing approach. This not only guarantees accuracy, but also facilitates seamless commutability of results across our AU chemistry and IA platforms within your entire network for all test volumes. The DxC 500i provides consistent, reliable, and easily comparable outcomes.
Alberto Scandroglio: This is really a thrilling time to be part of Beckman Coulter Diagnostics. Thank you Chelsea for sharing all these insights about the DxC 500i offers. So how can our customers learn more about this new low-volume integrated analyzer?
Chelsea Creech: Witness the impact first-hand. Laboratories worldwide are already reaping the rewards of the DxC 500i. This entire week will be dedicated to the DxC 500i. Follow along with us on social media as we share insights from across the globe, letting our customers experiences and successes tell the story.
Alberto Scandroglio: Thank you to our audience for being part of today's debut of DxC 500i Clinical Analyzer. We invite you to uncover how DxC 500i creates flexibility to drive productivity in your laboratory. So visit us at beckmancoulter.com/dxc500i or contact your sales or distributor for more information. Our dedicated team really stands ready to offer additional information and address any inquiries you may have. Together we can embark on the journey towards the future of healthcare and diagnostic testing with the DxC 500i Clinical Analyzer.

*Pending submission and clearance by the United States Food and Drug Administration; not yet available for in vitro diagnostic use in the U.S. For Investigational Use Only. The performance characteristics of this product have not been established.